<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1E362308-30EA-42A7-BD60-D9D29AD3BB97"><gtr:id>1E362308-30EA-42A7-BD60-D9D29AD3BB97</gtr:id><gtr:name>Proteo Biotech AG</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Centre for Cardiovascular Science</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1E362308-30EA-42A7-BD60-D9D29AD3BB97"><gtr:id>1E362308-30EA-42A7-BD60-D9D29AD3BB97</gtr:id><gtr:name>Proteo Biotech AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B287B1C9-187B-4D15-9F79-8428CC850ED2"><gtr:id>B287B1C9-187B-4D15-9F79-8428CC850ED2</gtr:id><gtr:firstName>Renzo</gtr:firstName><gtr:surname>Pessotto</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FB2B5561-13FB-48D7-B37C-C2E0C41A5263"><gtr:id>FB2B5561-13FB-48D7-B37C-C2E0C41A5263</gtr:id><gtr:firstName>Vipin</gtr:firstName><gtr:surname>Zamvar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A839116B-385D-4793-AA8C-45CA5A3B0622"><gtr:id>A839116B-385D-4793-AA8C-45CA5A3B0622</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Ernest</gtr:otherNames><gtr:surname>Newby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/58C7CF87-F10F-4183-B7AE-AC3CE25C3546"><gtr:id>58C7CF87-F10F-4183-B7AE-AC3CE25C3546</gtr:id><gtr:firstName>Scott</gtr:firstName><gtr:otherNames>Ian</gtr:otherNames><gtr:surname>Semple</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DD2C623A-F20A-46B2-9249-3EB77A4BAC69"><gtr:id>DD2C623A-F20A-46B2-9249-3EB77A4BAC69</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Henriksen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/95602773-E668-4E71-993D-EEB8E4D455AA"><gtr:id>95602773-E668-4E71-993D-EEB8E4D455AA</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:surname>McKillop</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001339"><gtr:id>FE6EE503-FA9D-404E-84A0-6C2B57E0151A</gtr:id><gtr:title>Developmental clinical studies- Effect of elafin on myocardial injury and inflammation in coronary artery bypass surgery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001339</gtr:grantReference><gtr:abstractText>Heart muscle cells are susceptible to injury and death following interruption of blood flow (myocardial ischaemia). A mild form of injury occurs during coronary artery bypass surgey and can be measured using a sensitive blood marker (troponin) providing a helpful model to study drugs that may reduce ischaemic injury. Neutrophils are circulating blood cells that contribute to ischaemic injury by releasing destructive enzymes (elastases). Humans produce a protein called elafin that reduces neutrophil elastase injury. Extensive preclinical work from different international centres indicates that elafin has a therapeutic role in diseases of the arteries and heart characterised by neutrophil mediated injury. We believe that administering elafin to patients undergoing bypass surgery will reduce neutrophil mediated myocardial injury and the rise in post-operative inflammatory activity. The degree of heart muscle damage occurring during ischaemia determines clinical outcomes. No therapies are available to address neutrophil mediated heart muscle injury and development of a drug to reduce this offers substantial clinical benefit.</gtr:abstractText><gtr:technicalSummary>During coronary artery bypass graft surgery, the myocardium receives an immediate ischaemic insult, exacerbated by post-ischaemic inflammatory responses following reperfusion that lead to increased myocardial injury. Elafin is a potent endogenous anti-elastase with wide ranging anti-inflammatory properties that inhibit destructive post-ischaemic inflammatory pathways. We hypothesise that elafin will reduce peri-operative ischaemic myocardial injury and systemic inflammation in elective coronary artery bypass graft surgery. Myocardial injury will be quantified over the first 48 hours using serial measurements of plasma troponin T concentrations. Subsequent myocardial infarct volume will be quantified by cardiac magnetic resonance imaging. This proof-of-concept study will establish whether elafin has cardioprotective effects in a clinical model of predictable myocardial injury. It has implications for the treatment of ischaemic heart disease, myocardial infarction and other diseases of ischaemic origin.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-15</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>352167</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Proteo Biotech AG</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>MRC Industrial Collaboration</gtr:description><gtr:id>E3D1F009-527A-44DE-A9E1-651047A03328</gtr:id><gtr:impact>The trial completed recruitment of 87 patients in September 2013. Results will be reported February 2014.
2 abstracts at American College of Cardiology Scientific Sessions 2013.</gtr:impact><gtr:partnerContribution>Provision of clinical grade Elafin.
Measurement of circulating elastase activity and Elafin concentrations.
Shipment costs</gtr:partnerContribution><gtr:piContribution>Set up and recruitment into a randomised controlled trial studying the effect of Elafin in coronary artery bypass surgery patients. Patient testing including blood tests and cardaic MRI scanning. Recruitment of 87 patients.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk to patient and funder support group for Chest Heart and Stroke Scotland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3350FD00-0D5E-488D-AD48-88382D0186F1</gtr:id><gtr:impact>This was a talk outlining how research funding had been used. It was given to supporters and fund raisers for CHSS.

There was useful discussion on the cost of running clinical trials and the challenges with recruitment</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk on medical research at international science festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>318D790B-0DD4-445E-9E31-1853DF5406E0</gtr:id><gtr:impact>75 members of the public attended the lecture as part of a series of talks at The Edinburgh International Science Festival

The talk resulted in useful audience discussion including discussion from patients about participating in clinical trials</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.sciencefestival.co.uk/uploads/Festival2014/EISFPROGRAM2014small5.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>14145</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ELHF Research Grants</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Edinburgh &amp; Lothians Health Foundation</gtr:fundingOrg><gtr:fundingRef>Dr Peter Henriksen</gtr:fundingRef><gtr:id>BB4674D8-DC13-4867-9FDF-941061EBCD2E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>74200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant R11/A135</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Chest Heart &amp; Stroke Scotland</gtr:fundingOrg><gtr:fundingRef>R11/A135</gtr:fundingRef><gtr:id>365A2A6D-E83D-4793-9776-306C34D1662D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The EMPIRE study is examining whether the anti-inflammatory drug Elafin can reduce peri-operative myocardial ischaemia and inflammation in patients undergoing coronary bypass surgery.</gtr:description><gtr:id>C4610A9A-A84B-4378-8C70-460211A36422</gtr:id><gtr:impact>The EMPIRE trial has completed recruitment of 87 patients. Results will be available February 2014</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>EMPIRE study</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN01253916</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN01253916</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The use of ultrasmall paramagnetic iron oxide particles as a smart contrast agent to detect inflammation within the myocardium in patients undergoing coronary bypass surgery.</gtr:description><gtr:id>B9800220-A902-4BA4-8F26-1380A1BE64A6</gtr:id><gtr:impact>We have been able to demonstrate increased USPIO signal in patients undergoing coronary bypass surgery. This represents myocardial inflammation. We will examine whether treatment with Elafin reduces myocardial inflammation and USPIO signal when EMPIRE study analysis is complete February 2013</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>EMPIRE trial- Imaging sub-study</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:ukcrnIsctnId>10717</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B384011D-EBE5-43CB-B2C4-464BBC298C39"><gtr:id>B384011D-EBE5-43CB-B2C4-464BBC298C39</gtr:id><gtr:title>The potential of neutrophil elastase inhibitors as anti-inflammatory therapies.</gtr:title><gtr:parentPublicationTitle>Current opinion in hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/497841b1668b12b5d4c834fc357919a1"><gtr:id>497841b1668b12b5d4c834fc357919a1</gtr:id><gtr:otherNames>Henriksen PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1065-6251</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF509098-41D8-4F91-A77F-E6F5B7BD13E7"><gtr:id>DF509098-41D8-4F91-A77F-E6F5B7BD13E7</gtr:id><gtr:title>INCIDENCE OF TYPE 5 MYOCARDIAL INFARCTION BY THE THIRD UNIVERSAL DEFINITION</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a401bad125f678b296b59fb837a26a38"><gtr:id>a401bad125f678b296b59fb837a26a38</gtr:id><gtr:otherNames>Alam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/757AE001-CD20-4E35-831E-9733F68BC8B7"><gtr:id>757AE001-CD20-4E35-831E-9733F68BC8B7</gtr:id><gtr:title>Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/834088852faa4b899b56202b16eae552"><gtr:id>834088852faa4b899b56202b16eae552</gtr:id><gtr:otherNames>Alam SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1EBF451D-FB42-4212-8FF9-BDB684C2CEA9"><gtr:id>1EBF451D-FB42-4212-8FF9-BDB684C2CEA9</gtr:id><gtr:title>Nanoparticle enhanced MRI scanning to detect cellular inflammation in experimental chronic renal allograft rejection.</gtr:title><gtr:parentPublicationTitle>International journal of molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/834088852faa4b899b56202b16eae552"><gtr:id>834088852faa4b899b56202b16eae552</gtr:id><gtr:otherNames>Alam SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2090-1720</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18EC51D5-EFAA-4F4E-8992-2514F7FC0358"><gtr:id>18EC51D5-EFAA-4F4E-8992-2514F7FC0358</gtr:id><gtr:title>Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trial.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/834088852faa4b899b56202b16eae552"><gtr:id>834088852faa4b899b56202b16eae552</gtr:id><gtr:otherNames>Alam SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD6F516B-FB1C-47B2-BB77-BBA39A833348"><gtr:id>FD6F516B-FB1C-47B2-BB77-BBA39A833348</gtr:id><gtr:title>Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/834088852faa4b899b56202b16eae552"><gtr:id>834088852faa4b899b56202b16eae552</gtr:id><gtr:otherNames>Alam SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1097-6647</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001339</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>